Neoadjuvant chemotherapy in locally advanced colon cancer.A phase II trial

医学 结直肠癌 帕尼单抗 奥沙利铂 内科学 卡培他滨 克拉斯 化疗 肿瘤科 临床终点 外科 癌症 临床试验 氟尿嘧啶
作者
Anders Jakobsen,Fahimeh Andersen,Anders Fischer,Lars Henrik Jensen,Jens Christian Riis Jørgensen,Olav Larsen,Jan Lindebjerg,John Pløen,Søren Rafael Rafaelsen,Jesper Vilandt
出处
期刊:Acta Oncologica [Taylor & Francis]
卷期号:54 (10): 1747-1753 被引量:85
标识
DOI:10.3109/0284186x.2015.1037007
摘要

Background. Neoadjuvant chemotherapy has proven valuable in several tumors, but it has not been elucidated in colon cancer. The present phase II trial addressed the issue in high-risk patients selected by computed tomography (CT) scan.Material and methods. Patients with resectable colon cancer fulfilling the following criteria were offered inclusion; Histopathological verification of adenocarcinoma, T3 tumor on CT scan with extramural tumor invasion > 5 mm or T4 tumor, age ≥ 18 years, PS ≤ 2, adequate hematology, and informed consent. Patients with KRAS, BRAF or PIK3CA mutation or unknown mutational status received three cycles of capecitabine 2000 mg/m2 days 1-14 q3w and oxaliplatin 130 mg iv day 1 q3w. Wild-type patients received the same chemotherapy supplemented with panitumumab 9 mg/kg iv q3w. After the operation, patients fulfilling the international criteria for adjuvant chemotherapy, i.e. high-risk stage II and III patients, received five cycles of the same chemotherapy without panitumumab. Patients not fulfilling the criteria were offered follow-up only. The primary endpoint was the fraction of patients not fulfilling the criteria for adjuvant chemotherapy (converted patients). Secondary endpoints were recurrence rate, disease-free survival (DFS), and toxicity.Results. The study included 77 patients. The conversion rate was 42% in the wild-type group compared to 51% in patients with a mutation. The cumulative recurrence rate in converted versus unconverted patients was 6% versus 32% (p = 0.005) translating into a three-year DFS of 94% versus 63% (p = 0.005).Conclusion. Neoadjuvant chemotherapy in colon cancer is feasible and the results suggest that a major part of the patients can be spared adjuvant chemotherapy. Validation in a randomized trial is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
华仔应助机灵飞阳采纳,获得10
3秒前
潘善若发布了新的文献求助10
3秒前
4秒前
陈少华完成签到 ,获得积分10
4秒前
下一秒发布了新的文献求助10
5秒前
杨乃彬完成签到,获得积分10
5秒前
取名叫做利完成签到,获得积分10
6秒前
赘婿应助喻义梅采纳,获得10
7秒前
小二郎应助小门采纳,获得10
8秒前
ll发布了新的文献求助10
11秒前
正直的鸿完成签到,获得积分10
16秒前
17秒前
万能图书馆应助高贵梦露采纳,获得10
18秒前
momo发布了新的文献求助10
20秒前
传奇3应助boltos采纳,获得10
21秒前
21秒前
22秒前
要减肥笑阳完成签到 ,获得积分10
23秒前
全若之发布了新的文献求助10
28秒前
Jasper应助momo采纳,获得10
30秒前
Kasom完成签到 ,获得积分10
37秒前
顺利一德完成签到,获得积分20
38秒前
香蕉觅云应助Afaq采纳,获得10
38秒前
38秒前
38秒前
manman完成签到,获得积分10
39秒前
39秒前
哈哈哈完成签到,获得积分10
39秒前
YamDaamCaa应助科研通管家采纳,获得30
40秒前
40秒前
领导范儿应助科研通管家采纳,获得10
40秒前
香蕉觅云应助科研通管家采纳,获得10
40秒前
40秒前
大个应助科研通管家采纳,获得10
40秒前
czh应助科研通管家采纳,获得20
40秒前
科研通AI2S应助科研通管家采纳,获得10
40秒前
酷波er应助科研通管家采纳,获得10
40秒前
纯情的天奇完成签到 ,获得积分10
42秒前
顺利一德发布了新的文献求助10
43秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989263
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253814
捐赠科研通 3270066
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136